Malignant Mesothelioma patients exhibiting antitumor immune responses have demonstrated improved survival. One of the most effective vaccination methods for generating potent-specific immune responses is based on recombinant viral vectors. Recent interest has focused on Fowlpox virus as a candidate mammalian vaccine due to its large cloning capacity, which can provide sustained expression of heterologous genes combined with an impeccable safety profile.

In this paper, P. Bertino et al. reveal that a variant of Fowlpox vector expressing the mesothelioma-relevant tumor associated antigen survivin (FP-surv) exerted a significant antitumor effect against experimental mesothelioma tumors in mice.

Here is a paper analyzing the intriguing possibility that epigenetic drugs may increase the immunogenic profile of mesothelioma, thereby enhancing the ability of an immune response to target the tumor. 
HDAC inhibitors and demethylating agents open the chromatin into a conformation that facilitates transcription not only of tumor suppressors but also of tumor antigens, such as NY-ESO-1, MAGE-A1 and MAGE-A3.